Advertisement
UK markets closed

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     

  • AIM

    755.28
    +2.16 (+0.29%)
     

  • GBP/EUR

    1.1676
    +0.0019 (+0.17%)
     

  • GBP/USD

    1.2498
    -0.0013 (-0.10%)
     

  • Bitcoin GBP

    51,172.87
    -518.45 (-1.00%)
     

  • CMC Crypto 200

    1,333.77
    -62.77 (-4.49%)
     

  • S&P 500

    5,109.33
    +60.91 (+1.21%)
     

  • DOW

    38,285.94
    +200.14 (+0.53%)
     

  • CRUDE OIL

    83.75
    +0.18 (+0.22%)
     

  • GOLD FUTURES

    2,350.40
    +7.90 (+0.34%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,161.01
    +243.73 (+1.36%)
     

  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

Why Axsome Therapeutics Stock Took a Step Backwards This Week

George Budwell, The Motley Fool
·2-min read
Why Axsome Therapeutics Stock Took a Step Backwards This Week

Shares of Axsome Therapeutics (NASDAQ: AXSM) lost 9.75% of their value through Thursday's closing bell this week, according to data from S&P Global Market Intelligence. The biotech's shares are currently well off of their 52-week highs due to a regulatory delay for its experimental major depressive disorder drug AXS-05. What's important to understand is that this regulatory hiccup reportedly centers around two issues with the company's analytical methods in the Chemistry, Manufacturing, and Controls section of the New Drug Application submitted to the Food and Drug Administration (FDA).

Continue reading